Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 7/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761950 | 0.89 | HPGD (0.48) | FGFR1HPGDAOC3RAB9AALDH1A1 | |
| SCHEMBL1761944 | 0.85 | HPGD (0.48) | FGFR1HPGDAOC3RAB9AALDH1A1 | |
| SCHEMBL1761560 | 0.81 | HPGD (0.45) | FGFR1HPGDAOC3KDR | |
| SCHEMBL1761744 | 0.81 | HPGD (0.45) | FGFR1HPGDAOC3KDR | |
| SCHEMBL1762101 | 0.81 | GABRA1 (0.55) | FGFR1HPGDAOC3KDR | |
| SCHEMBL1761724 | 0.81 | KDR (0.45) | FGFR1HPGDALDH1A1GLAKDR | |
| SCHEMBL1761786 | 0.80 | FGFR1 (0.54) | FGFR1HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL1761990 | 0.78 | HPGD (0.57) | FGFR1HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL1761664 | 0.78 | HPGD (0.48) | FGFR1HPGDAOC3RAB9AALDH1A1 | |
| SCHEMBL1761977 | 0.75 | FGFR1 (0.67) | FGFR1HPGDRAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288418-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2012-10-16 | — | — | US | disclosed |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2011-05-19 | — | — | US | disclosed |
| EP-2319837-A1 | Benzimidazole derivatives and their use for modulating the GABAa receptor complex | NeuroSearch AS (DK) | 2011-05-11 | — | — | EP | disclosed |
| US-7902230-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2011-03-08 | — | — | US | disclosed |
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | SANIONA A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036476-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885HPGD 1966/4885AOC3 1046/4885 |
| US-20110118259-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | GABRB2, GABRB1, GABRB3 | FGFR1 3907/4885HPGD 1966/4885AOC3 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.